Enhanced recovery program successfully reduced opioid use after pancreatic cancer surgery

Engineered gut bacteria, BifidoSumIL-2, shows promise against pancreatic cancer

Cancer immunotherapies have transformed treatment for many cancers, but pancreatic cancer remains especially difficult to treat.

July 31, 2026

Vol.52 No.30

In Brief

LSU LCMC Health cancer center researchers receive $3.1M NIH grant to study pancreatic cancer

LSU Health New Orleans received a five-year, $3.1 million NIH grant to support pancreatic cancer research led by investigators in the LSU LCMC Health Cancer Center.

July 17, 2026

Vol.52 No.28

Clinical Roundup

Experimental KRAS vaccine generates immune response against pancreatic cancer in people at high risk, phase I study finds

Researchers at the Johns Hopkins Kimmel Cancer Center and its Skip Viragh Center for Pancreatic Cancer have reported that an experimental vaccine targeting mutant KRAS, one of the most common genetic drivers of pancreatic cancer, was safe and generated durable immune responses aimed at preventing the cancer in people at high risk.

July 17, 2026

Vol.52 No.28

Clinical Roundup

Zoldonrasib + daraxonrasib show 81% ORR in patients with RAS G12D metastatic pancreatic cancer, phase I/II study finds

Zoldonrasib, an oral RAS(ON) G12D-selective covalent inhibitor, in combination with daraxonrasib showed 81% objective response rate compared to zoldonrasib in combination with standard of care chemotherapy in previously untreated patients with RAS G12D metastatic pancreatic ductal adenocarcinoma, according to results of two phase I/II study.

July 10, 2026

Vol.52 No.27

Clinical Roundup

Tumor-on-a-chip model shows how pancreatic cancer hijacks immune cells, UMiami study finds

A “tumor-on-a-chip” model is giving scientists a live look at how pancreatic cancer can recruit the body’s own immune cells to help tumors survive. The study reveals possible new targets to weaken the cancer’s defenses and make treatments work better.

July 10, 2026

Vol.52 No.27

In the Archives

Robert Mayer tells us about pancreatic cancer’s hopeless past as new data shows promise

When Robert Mayer was only a few years out of residency, in the 1970s, he signed on as an investigator of the NCI-supported Gastrointestinal Tumor Study Group, which conducted research into colorectal, gastric, and pancreatic cancers.

June 26, 2026

Vol.52 No.25

By Sara Willa Ernst

Enhanced recovery program successfully reduced opioid use after pancreatic cancer surgery

YOU MAY BE INTERESTED IN

Engineered gut bacteria, BifidoSumIL-2, shows promise against pancreatic cancer

LSU LCMC Health cancer center researchers receive $3.1M NIH grant to study pancreatic cancer

Experimental KRAS vaccine generates immune response against pancreatic cancer in people at high risk, phase I study finds

Zoldonrasib + daraxonrasib show 81% ORR in patients with RAS G12D metastatic pancreatic cancer, phase I/II study finds

Tumor-on-a-chip model shows how pancreatic cancer hijacks immune cells, UMiami study finds

Robert Mayer tells us about pancreatic cancer’s hopeless past as new data shows promise

Renew today!

Subscriber content

Never miss an issue!

Login